Pet Cancer Therapeutics Market Size, Trends and Insights By Therapy (Chemotherapy, Immunotherapy, Targeted Therapy, Combination Therapy, Others), By Cancer Type (Lymphoma, Mast Cell Cancer, Melanoma, Mammary and Squamous Cell Cancer, Others), By Route of Administration (Oral, Injection), By Pet Type (Dog, Cat), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033
Report Snapshot
| Study Period: | 2024-2033 |
| Fastest Growing Market: | Asia-Pacific |
| Largest Market: | Europe |
Major Players
- Zoetis Inc.
- Elanco Animal Health
- Boehringer Ingelheim Animal Health
- Virbac
- Aratana Therapeutics
- Others
Reports Description
As per the current market research conducted by the CMI Team, the global Pet Cancer Therapeutics Market is expected to record a CAGR of 9.2% from 2024 to 2033. In 2024, the market size is projected to reach a valuation of USD 526.5 Million. By 2033, the valuation is anticipated to reach USD 1,162.4 Million.
The Pet Cancer Therapeutics market refers to the segment of the veterinary industry dedicated to developing and providing treatments for cancer in companion animals. It encompasses a wide range of pharmaceuticals, biologics, and therapeutic interventions designed to diagnose, manage, and treat various types of cancer in pets.
With the growing prevalence of cancer in companion animals and the increasing demand for advanced veterinary care, the Pet Cancer Therapeutics market plays a crucial role in addressing the healthcare needs of pets affected by cancer, improving their quality of life, and supporting their owners through treatment options and support services.
Pet Cancer Therapeutics Market – Significant Growth Factors
The Pet Cancer Therapeutics Market presents significant growth opportunities due to several factors:
- Increasing Pet Ownership: The rising number of pet owners, coupled with the growing trend of pet humanization, has led to increased spending on pet healthcare, including cancer therapeutics.
- Advancements in Veterinary Medicine: Ongoing advancements in veterinary oncology, including new treatment modalities, diagnostic tools, and targeted therapies, are driving the development of innovative cancer therapeutics for pets.
- Rising Incidence of Pet Cancer: The increasing prevalence of cancer among companion animals, attributed to factors such as environmental pollutants, genetic predispositions, and aging populations, is boosting the demand for effective cancer therapeutics.
- Growing Awareness and Education: Pet owners are becoming more aware of the signs and symptoms of cancer in pets, leading to earlier diagnosis and intervention. This heightened awareness, coupled with increased education efforts by veterinary professionals, is driving demand for pet cancer therapeutics.
- Personalized Medicine for Pets: The emergence of personalized medicine approaches, such as genomic testing and targeted therapies, presents an opportunity to tailor cancer treatments to the individual needs of pets, improving treatment outcomes and minimizing side effects.
- Expansion of Telemedicine and Remote Consultations: The adoption of telemedicine and remote consultations in veterinary oncology allows for greater access to specialized care, particularly in underserved areas. This presents an opportunity to expand the reach of pet cancer therapeutics and improve patient outcomes through remote diagnosis, treatment planning, and follow-up care.
Pet Cancer Therapeutics Market – Mergers and Acquisitions
The Pet Cancer Therapeutics Market has seen several mergers and acquisitions in recent years, with companies seeking to expand their market presence and leverage synergies to improve their product offerings and profitability. Some notable examples of mergers and acquisitions in the Pet Cancer Therapeutics Market include:
- In 2023, Hill’s Pet Nutrition introduced Prescription Diet ONC Care, a therapeutic pet diet aimed at addressing appetite loss and providing high-quality nutrition for cats and dogs diagnosed with cancer. This specialized diet is designed to support the unique nutritional needs of pets undergoing cancer treatment.
- In 2022, Boehringer Ingelheim and CarthroniX have partnered to advance canine oncology by developing innovative small molecule therapeutics. This collaboration aims to address the unmet medical needs of dogs diagnosed with cancer, leveraging CarthroniX’s expertise in small molecule-based therapies.
- In 2021, PetDx, a San Diego-based startup, raised USD 62 million in its Series B funding round to expand the adoption of its cancer-detecting blood test for dogs, known as OncoK9. The company aims to make OncoK9 a standard test in pet clinics nationwide.
These mergers and acquisitions have helped companies expand their product offerings, improve their market presence, and capitalize on growth opportunities in the Pet Cancer Therapeutics Market. The trend is expected to continue as companies seek to gain a competitive edge in the market.
COMPARATIVE ANALYSIS OF THE RELATED MARKET
| Pet Cancer Therapeutics Market | Ligating Clips Market | Syringe Filter Market |
| CAGR 9.2% (Approx) | CAGR 25.1% (Approx) | CAGR 6.2% (Approx) |
| USD 1,162.4 Million by 2033 | USD 2495.3 Million by 2032 | USD 28.3 Billion by 2032 |
Pet Cancer Therapeutics Market – Significant Threats
The Pet Cancer Therapeutics Market faces several significant threats that could impact its growth and profitability in the future. Some of these threats include:
- High Treatment Costs: The cost of cancer treatment for pets can be prohibitively expensive for some pet owners, leading to financial constraints and potential delays or refusal of treatment, which could impact the demand for pet cancer therapeutics.
- Limited Access to Specialized Care: Limited access to specialized veterinary oncology services in certain regions may restrict pet owners’ ability to seek advanced cancer treatments for their pets, affecting the adoption and utilization of pet cancer therapeutics.
- Regulatory Challenges: Stringent regulatory requirements for veterinary drugs and therapies, including clinical trial regulations and approval processes, can pose challenges for companies developing and commercializing pet cancer therapeutics, potentially delaying market entry and innovation.
- Competition from Alternative Therapies: Competition from alternative therapies, such as holistic treatments, herbal remedies, or dietary supplements, may divert pet owners’ attention and resources away from traditional pet cancer therapeutics, impacting market demand and revenue potential.
- Limited Awareness and Education: Lack of awareness and education among pet owners about the availability and benefits of pet cancer therapeutics, as well as misconceptions about treatment options and outcomes, may hinder market growth and adoption of advanced cancer treatments for pets.
Category-Wise Insights:
By Therapy
- Chemotherapy: Chemotherapy involves the use of drugs to kill cancer cells or slow their growth. In the Pet Cancer Therapeutics Market, chemotherapy remains a primary treatment modality, with ongoing trends focusing on the development of more targeted and less toxic chemotherapy agents tailored to pets’ needs.
- Immunotherapy: Immunotherapy boosts the body’s immune system to fight cancer. In the Pet Cancer Therapeutics Market, immunotherapy is gaining traction as a promising treatment option, with trends emphasizing the development of novel immunotherapeutic agents and personalized immunotherapy approaches for pets.
- Targeted Therapy: Targeted therapy blocks specific molecules involved in cancer cell growth. In the Pet Cancer Therapeutics Market, targeted therapy is experiencing rapid growth, with trends focusing on the discovery of new molecular targets, precision medicine approaches, and the development of targeted therapeutics tailored to pets’ genetic profiles.
- Combination Therapy: Combination therapy involves using multiple treatment modalities simultaneously or sequentially to enhance efficacy. In the Pet Cancer Therapeutics Market, combination therapy is a growing trend, with research focusing on identifying synergistic treatment combinations and optimizing treatment regimens to improve outcomes for pets with cancer.
By Cancer Type
- Lymphoma: Lymphoma is a common cancer affecting lymphocytes. In the pet cancer therapeutics market, advancements in targeted therapies and immunotherapies have improved treatment outcomes. Rising incidence rates and increasing demand for personalized medicine are driving market growth.
- Mast Cell Cancer: Mast cell cancer involves abnormal growth of mast cells. In the pet cancer therapeutics market, targeted therapies and surgical interventions are key treatment modalities. Growing awareness and early detection initiatives are influencing market trends.
- Melanoma: Melanoma is a malignant tumor arising from melanocytes. In the pet cancer therapeutics market, innovative immunotherapies and vaccine-based treatments show promise. Increasing prevalence and advancements in early diagnosis are shaping market dynamics.
- Mammary and Squamous Cell Cancer: Mammary and squamous cell cancer affect glandular and epithelial tissues, respectively. In the pet cancer therapeutics market, surgical excision and chemotherapy are common treatment approaches. Rising incidence rates and efforts to improve treatment efficacy are key trends.
- Others: Other types of pet cancers include osteosarcoma, hemangiosarcoma, and oral tumors. The pet cancer therapeutics market addresses these cancers through a combination of surgery, chemotherapy, and radiation therapy. Continued research and development efforts drive innovation in treatment options for these cancers.
By Route of Administration
- Oral: Oral administration involves delivering pet cancer therapeutics through the mouth, typically in the form of tablets, capsules, or liquids, allowing for convenient and non-invasive treatment options. The oral route of administration is witnessing growth due to the development of novel oral formulations and increased preference for at-home treatments, enhancing convenience for pet owners.
- Injection: Injection administration delivers pet cancer therapeutics directly into the body through subcutaneous, intramuscular, or intravenous routes, providing rapid and targeted delivery of medications. Injections are gaining popularity in the Pet Cancer Therapeutics Market due to advancements in injectable formulations, such as long-acting formulations and targeted drug delivery systems, improving treatment efficacy and patient compliance.
By Pet Type
- Dog: In the pet cancer therapeutics market, canine cancer therapeutics refer to treatments tailored specifically for dogs diagnosed with cancer. Trends include increasing adoption of targeted therapies and immunotherapies, advancements in surgical techniques, and a growing focus on personalized medicine approaches to improve treatment outcomes for canine cancer patients.
- Cat: Feline cancer therapeutics in the pet cancer therapeutics market are specialized treatments designed for cats diagnosed with cancer. Trends include the development of novel chemotherapy agents and radiation therapies specifically formulated for feline patients, as well as advancements in diagnostic imaging technologies for early detection and treatment monitoring in cats with cancer.
Report Scope
| Feature of the Report | Details |
| Market Size in 2024 | USD 526.5 Million |
| Projected Market Size in 2033 | USD 1,162.4 Million |
| Market Size in 2023 | USD 482.1 Million |
| CAGR Growth Rate | 9.2% CAGR |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Key Segment | By Therapy, Cancer Type, Route of Administration, Pet Type and Region |
| Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends |
| Regional Scope | North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America |
| Buying Options | Request tailored purchasing options to fulfil your requirements for research. |
Pet Cancer Therapeutics Market – Regional Analysis
The Pet Cancer Therapeutics Market is segmented into various regions, including North America, Europe, Asia-Pacific, and LAMEA. Here is a brief overview of each region:
- North America: In North America, the pet cancer therapeutics market is characterized by a high level of technological advancements and a strong focus on research and development. Trends include the increasing adoption of personalized medicine approaches, such as genomic testing and targeted therapies, as well as the growing demand for minimally invasive surgical techniques and novel immunotherapies for pets diagnosed with cancer.
- Europe: In Europe, the pet cancer therapeutics market is influenced by a growing emphasis on preventive care and early detection of cancer in pets. Trends include the expansion of pet insurance coverage for cancer treatments, the adoption of telemedicine and remote consultations in veterinary oncology, and the implementation of comprehensive cancer screening programs for companion animals.
- Asia-Pacific: The Asia-Pacific region is experiencing rapid growth in the pet cancer therapeutics market due to increasing pet ownership rates and rising disposable incomes. Trends include the emergence of specialized veterinary oncology centers and cancer treatment facilities, the adoption of alternative and complementary therapies for pets with cancer, and the development of affordable and accessible cancer treatments tailored to the unique needs of pets in the region.
- LAMEA (Latin America, Middle East, and Africa): In LAMEA, the pet cancer therapeutics market is characterized by a growing awareness of pet health issues and a rising demand for advanced veterinary care. Trends include the expansion of veterinary oncology services in urban centers, the adoption of telemedicine and digital health solutions to improve access to cancer diagnostics and treatment, and the development of culturally relevant and affordable cancer therapeutics for pets in emerging markets.
Competitive Landscape – Pet Cancer Therapeutics Market
The Pet Cancer Therapeutics Market is highly competitive, with a large number of manufacturers and retailers operating globally. Some of the key players in the market include:
- Zoetis Inc.
- Elanco Animal Health
- Boehringer Ingelheim Animal Health
- Virbac
- Aratana Therapeutics
- AB Science
- VetDC Inc.
- Regeneus Ltd.
- CanFel Therapeutics
- Merial
- Karyopharm Therapeutics Inc.
- Rhizen Pharmaceuticals SA
- Vetoquinol S.A.
- Ceva Santé Animale
- Sentia Medical Sciences Inc.
- Others
These companies operate in the market through various strategies such as product innovation, mergers and acquisitions, and partnerships.
New players entering the pet cancer therapeutics market are adopting innovative approaches to differentiate themselves and gain traction. Companies like PetVivo Holdings Inc., OncoPet Diagnostics, and VetDC, Inc. are leveraging advancements in biotechnology, diagnostics, and targeted therapies to develop novel cancer treatments for pets.
Meanwhile, key players such as Zoetis Inc., Elanco Animal Health, and Boehringer Ingelheim Animal Health dominate the market due to their extensive product portfolios, global presence, established distribution networks, and strong research and development capabilities, which enable them to offer comprehensive solutions and maintain market leadership.
The Pet Cancer Therapeutics Market is segmented as follows:
By Therapy
- Chemotherapy
- Immunotherapy
- Targeted Therapy
- Combination Therapy
- Others
By Cancer Type
- Lymphoma
- Mast Cell Cancer
- Melanoma
- Mammary and Squamous Cell Cancer
- Others
By Route of Administration
- Oral
- Injection
By Pet Type
- Dog
- Cat
Regional Coverage:
North America
- U.S.
- Canada
- Mexico
- Rest of North America
Europe
- Germany
- France
- U.K.
- Russia
- Italy
- Spain
- Netherlands
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Taiwan
- Rest of Asia Pacific
The Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of the Middle East & Africa
Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
- Chapter 1. Preface
- 1.1 Report Description and Scope
- 1.2 Research scope
- 1.3 Research methodology
- 1.3.1 Market Research Type
- 1.3.2 Market Research Methodology
- Chapter 2. Executive Summary
- 2.1 Global Pet Cancer Therapeutics Market, (2024 – 2033) (USD Million)
- 2.2 Global Pet Cancer Therapeutics Market: snapshot
- Chapter 3. Global Pet Cancer Therapeutics Market – Industry Analysis
- 3.1 Pet Cancer Therapeutics Market: Market Dynamics
- 3.2 Market Drivers
- 3.2.1 Increasing Pet Ownership
- 3.2.2 Advancements in Veterinary Medicine
- 3.2.3 Rising Incidence of Pet Cancer
- 3.2.4 Growing Awareness and Education
- 3.2.5 Personalized Medicine for Pets
- 3.2.6 Expansion of Telemedicine and Remote Consultations.
- 3.3 Market Restraints
- 3.4 Market Opportunities
- 3.5 Market Challenges
- 3.6 Porter’s Five Forces Analysis
- 3.7 Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Therapy
- 3.7.2 Market Attractiveness Analysis By Cancer Type
- 3.7.3 Market Attractiveness Analysis By Route of Administration
- 3.7.4 Market Attractiveness Analysis By Pet Type
- Chapter 4. Global Pet Cancer Therapeutics Market- Competitive Landscape
- 4.1 Company market share analysis
- 4.1.1 Global Pet Cancer Therapeutics Market: company market share, 2024
- 4.2 Strategic development
- 4.2.1 Acquisitions & mergers
- 4.2.2 New Product launches
- 4.2.3 Agreements, partnerships, cullaborations, and joint ventures
- 4.2.4 Research and development and Regional expansion
- 4.3 Price trend analysis
- 4.1 Company market share analysis
- Chapter 5. Global Pet Cancer Therapeutics Market – Therapy Analysis
- 5.1 Global Pet Cancer Therapeutics Market Overview: By Therapy
- 5.1.1 Global Pet Cancer Therapeutics Market Share, By Therapy, 2024 and – 2033
- 5.2 Chemotherapy
- 5.2.1 Global Pet Cancer Therapeutics Market by Chemotherapy, 2024 – 2033 (USD Million)
- 5.3 Immunotherapy
- 5.3.1 Global Pet Cancer Therapeutics Market by Immunotherapy, 2024 – 2033 (USD Million)
- 5.4 Targeted Therapy
- 5.4.1 Global Pet Cancer Therapeutics Market by Targeted Therapy, 2024 – 2033 (USD Million)
- 5.5 Combination Therapy
- 5.5.1 Global Pet Cancer Therapeutics Market by Combination Therapy, 2024 – 2033 (USD Million)
- 5.6 Others
- 5.6.1 Global Pet Cancer Therapeutics Market by Others, 2024 – 2033 (USD Million)
- 5.1 Global Pet Cancer Therapeutics Market Overview: By Therapy
- Chapter 6. Global Pet Cancer Therapeutics Market – Cancer Type Analysis
- 6.1 Global Pet Cancer Therapeutics Market Overview: By Cancer Type
- 6.1.1 Global Pet Cancer Therapeutics Market Share, By Cancer Type, 2024 and – 2033
- 6.2 Lymphoma
- 6.2.1 Global Pet Cancer Therapeutics Market by Lymphoma, 2024 – 2033 (USD Million)
- 6.3 Mast Cell Cancer
- 6.3.1 Global Pet Cancer Therapeutics Market by Mast Cell Cancer, 2024 – 2033 (USD Million)
- 6.4 Melanoma
- 6.4.1 Global Pet Cancer Therapeutics Market by Melanoma, 2024 – 2033 (USD Million)
- 6.5 Mammary and Squamous Cell Cancer
- 6.5.1 Global Pet Cancer Therapeutics Market by Mammary and Squamous Cell Cancer, 2024 – 2033 (USD Million)
- 6.6 Others
- 6.6.1 Global Pet Cancer Therapeutics Market by Others, 2024 – 2033 (USD Million)
- 6.1 Global Pet Cancer Therapeutics Market Overview: By Cancer Type
- Chapter 7. Global Pet Cancer Therapeutics Market – Route of Administration Analysis
- 7.1 Global Pet Cancer Therapeutics Market Overview: By Route of Administration
- 7.1.1 Global Pet Cancer Therapeutics Market Share, By Route of Administration, 2024 and – 2033
- 7.2 Oral
- 7.2.1 Global Pet Cancer Therapeutics Market by Oral, 2024 – 2033 (USD Million)
- 7.3 Injection
- 7.3.1 Global Pet Cancer Therapeutics Market by Injection, 2024 – 2033 (USD Million)
- 7.1 Global Pet Cancer Therapeutics Market Overview: By Route of Administration
- Chapter 8. Global Pet Cancer Therapeutics Market – Pet Type Analysis
- 8.1 Global Pet Cancer Therapeutics Market Overview: By Pet Type
- 8.1.1 Global Pet Cancer Therapeutics Market Share, By Pet Type, 2024 and – 2033
- 8.2 Dog
- 8.2.1 Global Pet Cancer Therapeutics Market by Dog, 2024 – 2033 (USD Million)
- 8.3 Cat
- 8.3.1 Global Pet Cancer Therapeutics Market by Cat, 2024 – 2033 (USD Million)
- 8.1 Global Pet Cancer Therapeutics Market Overview: By Pet Type
- Chapter 9. Pet Cancer Therapeutics Market – Regional Analysis
- 9.1 Global Pet Cancer Therapeutics Market Regional Overview
- 9.2 Global Pet Cancer Therapeutics Market Share, by Region, 2024 & – 2033 (USD Million)
- 9.3. North America
- 9.3.1 North America Pet Cancer Therapeutics Market, 2024 – 2033 (USD Million)
- 9.3.1.1 North America Pet Cancer Therapeutics Market, by Country, 2024 – 2033 (USD Million)
- 9.3.1 North America Pet Cancer Therapeutics Market, 2024 – 2033 (USD Million)
- 9.4 North America Pet Cancer Therapeutics Market, by Therapy, 2024 – 2033
- 9.4.1 North America Pet Cancer Therapeutics Market, by Therapy, 2024 – 2033 (USD Million)
- 9.5 North America Pet Cancer Therapeutics Market, by Cancer Type, 2024 – 2033
- 9.5.1 North America Pet Cancer Therapeutics Market, by Cancer Type, 2024 – 2033 (USD Million)
- 9.6 North America Pet Cancer Therapeutics Market, by Route of Administration, 2024 – 2033
- 9.6.1 North America Pet Cancer Therapeutics Market, by Route of Administration, 2024 – 2033 (USD Million)
- 9.7 North America Pet Cancer Therapeutics Market, by Pet Type, 2024 – 2033
- 9.7.1 North America Pet Cancer Therapeutics Market, by Pet Type, 2024 – 2033 (USD Million)
- 9.8. Europe
- 9.8.1 Europe Pet Cancer Therapeutics Market, 2024 – 2033 (USD Million)
- 9.8.1.1 Europe Pet Cancer Therapeutics Market, by Country, 2024 – 2033 (USD Million)
- 9.8.1 Europe Pet Cancer Therapeutics Market, 2024 – 2033 (USD Million)
- 9.9 Europe Pet Cancer Therapeutics Market, by Therapy, 2024 – 2033
- 9.9.1 Europe Pet Cancer Therapeutics Market, by Therapy, 2024 – 2033 (USD Million)
- 9.10 Europe Pet Cancer Therapeutics Market, by Cancer Type, 2024 – 2033
- 9.10.1 Europe Pet Cancer Therapeutics Market, by Cancer Type, 2024 – 2033 (USD Million)
- 9.11 Europe Pet Cancer Therapeutics Market, by Route of Administration, 2024 – 2033
- 9.11.1 Europe Pet Cancer Therapeutics Market, by Route of Administration, 2024 – 2033 (USD Million)
- 9.12 Europe Pet Cancer Therapeutics Market, by Pet Type, 2024 – 2033
- 9.12.1 Europe Pet Cancer Therapeutics Market, by Pet Type, 2024 – 2033 (USD Million)
- 9.13. Asia Pacific
- 9.13.1 Asia Pacific Pet Cancer Therapeutics Market, 2024 – 2033 (USD Million)
- 9.13.1.1 Asia Pacific Pet Cancer Therapeutics Market, by Country, 2024 – 2033 (USD Million)
- 9.13.1 Asia Pacific Pet Cancer Therapeutics Market, 2024 – 2033 (USD Million)
- 9.14 Asia Pacific Pet Cancer Therapeutics Market, by Therapy, 2024 – 2033
- 9.14.1 Asia Pacific Pet Cancer Therapeutics Market, by Therapy, 2024 – 2033 (USD Million)
- 9.15 Asia Pacific Pet Cancer Therapeutics Market, by Cancer Type, 2024 – 2033
- 9.15.1 Asia Pacific Pet Cancer Therapeutics Market, by Cancer Type, 2024 – 2033 (USD Million)
- 9.16 Asia Pacific Pet Cancer Therapeutics Market, by Route of Administration, 2024 – 2033
- 9.16.1 Asia Pacific Pet Cancer Therapeutics Market, by Route of Administration, 2024 – 2033 (USD Million)
- 9.17 Asia Pacific Pet Cancer Therapeutics Market, by Pet Type, 2024 – 2033
- 9.17.1 Asia Pacific Pet Cancer Therapeutics Market, by Pet Type, 2024 – 2033 (USD Million)
- 9.18. Latin America
- 9.18.1 Latin America Pet Cancer Therapeutics Market, 2024 – 2033 (USD Million)
- 9.18.1.1 Latin America Pet Cancer Therapeutics Market, by Country, 2024 – 2033 (USD Million)
- 9.18.1 Latin America Pet Cancer Therapeutics Market, 2024 – 2033 (USD Million)
- 9.19 Latin America Pet Cancer Therapeutics Market, by Therapy, 2024 – 2033
- 9.19.1 Latin America Pet Cancer Therapeutics Market, by Therapy, 2024 – 2033 (USD Million)
- 9.20 Latin America Pet Cancer Therapeutics Market, by Cancer Type, 2024 – 2033
- 9.20.1 Latin America Pet Cancer Therapeutics Market, by Cancer Type, 2024 – 2033 (USD Million)
- 9.21 Latin America Pet Cancer Therapeutics Market, by Route of Administration, 2024 – 2033
- 9.21.1 Latin America Pet Cancer Therapeutics Market, by Route of Administration, 2024 – 2033 (USD Million)
- 9.22 Latin America Pet Cancer Therapeutics Market, by Pet Type, 2024 – 2033
- 9.22.1 Latin America Pet Cancer Therapeutics Market, by Pet Type, 2024 – 2033 (USD Million)
- 9.23. The Middle-East and Africa
- 9.23.1 The Middle-East and Africa Pet Cancer Therapeutics Market, 2024 – 2033 (USD Million)
- 9.23.1.1 The Middle-East and Africa Pet Cancer Therapeutics Market, by Country, 2024 – 2033 (USD Million)
- 9.23.1 The Middle-East and Africa Pet Cancer Therapeutics Market, 2024 – 2033 (USD Million)
- 9.24 The Middle-East and Africa Pet Cancer Therapeutics Market, by Therapy, 2024 – 2033
- 9.24.1 The Middle-East and Africa Pet Cancer Therapeutics Market, by Therapy, 2024 – 2033 (USD Million)
- 9.25 The Middle-East and Africa Pet Cancer Therapeutics Market, by Cancer Type, 2024 – 2033
- 9.25.1 The Middle-East and Africa Pet Cancer Therapeutics Market, by Cancer Type, 2024 – 2033 (USD Million)
- 9.26 The Middle-East and Africa Pet Cancer Therapeutics Market, by Route of Administration, 2024 – 2033
- 9.26.1 The Middle-East and Africa Pet Cancer Therapeutics Market, by Route of Administration, 2024 – 2033 (USD Million)
- 9.27 The Middle-East and Africa Pet Cancer Therapeutics Market, by Pet Type, 2024 – 2033
- 9.27.1 The Middle-East and Africa Pet Cancer Therapeutics Market, by Pet Type, 2024 – 2033 (USD Million)
- Chapter 10. Company Profiles
- 10.1 Zoetis Inc.
- 10.1.1 Overview
- 10.1.2 Financials
- 10.1.3 Product Portfolio
- 10.1.4 Business Strategy
- 10.1.5 Recent Developments
- 10.2 Elanco Animal Health
- 10.2.1 Overview
- 10.2.2 Financials
- 10.2.3 Product Portfolio
- 10.2.4 Business Strategy
- 10.2.5 Recent Developments
- 10.3 Boehringer Ingelheim Animal Health
- 10.3.1 Overview
- 10.3.2 Financials
- 10.3.3 Product Portfolio
- 10.3.4 Business Strategy
- 10.3.5 Recent Developments
- 10.4 Virbac
- 10.4.1 Overview
- 10.4.2 Financials
- 10.4.3 Product Portfolio
- 10.4.4 Business Strategy
- 10.4.5 Recent Developments
- 10.5 Aratana Therapeutics
- 10.5.1 Overview
- 10.5.2 Financials
- 10.5.3 Product Portfolio
- 10.5.4 Business Strategy
- 10.5.5 Recent Developments
- 10.6 AB Science
- 10.6.1 Overview
- 10.6.2 Financials
- 10.6.3 Product Portfolio
- 10.6.4 Business Strategy
- 10.6.5 Recent Developments
- 10.7 VetDC Inc.
- 10.7.1 Overview
- 10.7.2 Financials
- 10.7.3 Product Portfolio
- 10.7.4 Business Strategy
- 10.7.5 Recent Developments
- 10.8 Regeneus Ltd.
- 10.8.1 Overview
- 10.8.2 Financials
- 10.8.3 Product Portfolio
- 10.8.4 Business Strategy
- 10.8.5 Recent Developments
- 10.9 CanFel Therapeutics
- 10.9.1 Overview
- 10.9.2 Financials
- 10.9.3 Product Portfolio
- 10.9.4 Business Strategy
- 10.9.5 Recent Developments
- 10.10 Merial
- 10.10.1 Overview
- 10.10.2 Financials
- 10.10.3 Product Portfolio
- 10.10.4 Business Strategy
- 10.10.5 Recent Developments
- 10.11 Karyopharm Therapeutics Inc.
- 10.11.1 Overview
- 10.11.2 Financials
- 10.11.3 Product Portfolio
- 10.11.4 Business Strategy
- 10.11.5 Recent Developments
- 10.12 Rhizen Pharmaceuticals SA
- 10.12.1 Overview
- 10.12.2 Financials
- 10.12.3 Product Portfolio
- 10.12.4 Business Strategy
- 10.12.5 Recent Developments
- 10.13 Vetoquinol S.A.
- 10.13.1 Overview
- 10.13.2 Financials
- 10.13.3 Product Portfolio
- 10.13.4 Business Strategy
- 10.13.5 Recent Developments
- 10.14 Ceva Santé Animale
- 10.14.1 Overview
- 10.14.2 Financials
- 10.14.3 Product Portfolio
- 10.14.4 Business Strategy
- 10.14.5 Recent Developments
- 10.15 Sentia Medical Sciences Inc.
- 10.15.1 Overview
- 10.15.2 Financials
- 10.15.3 Product Portfolio
- 10.15.4 Business Strategy
- 10.15.5 Recent Developments
- 10.16 Others.
- 10.16.1 Overview
- 10.16.2 Financials
- 10.16.3 Product Portfolio
- 10.16.4 Business Strategy
- 10.16.5 Recent Developments
- 10.1 Zoetis Inc.
List Of Figures
Figures No 1 to 32
List Of Tables
Tables No 1 to 102
Report Methodology
In order to get the most precise estimates and forecasts possible, Custom Market Insights applies a detailed and adaptive research methodology centered on reducing deviations. For segregating and assessing quantitative aspects of the market, the company uses a combination of top-down and bottom-up approaches. Furthermore, data triangulation, which examines the market from three different aspects, is a recurring theme in all of our research reports. The following are critical components of the methodology used in all of our studies:
Preliminary Data Mining
On a broad scale, raw market information is retrieved and compiled. Data is constantly screened to make sure that only substantiated and verified sources are taken into account. Furthermore, data is mined from a plethora of reports in our archive and also a number of reputed & reliable paid databases. To gain a detailed understanding of the business, it is necessary to know the entire product life cycle and to facilitate this, we gather data from different suppliers, distributors, and buyers.
Surveys, technological conferences, and trade magazines are used to identify technical issues and trends. Technical data is also gathered from the standpoint of intellectual property, with a focus on freedom of movement and white space. The dynamics of the industry in terms of drivers, restraints, and valuation trends are also gathered. As a result, the content created contains a diverse range of original data, which is then cross-validated and verified with published sources.
Statistical Model
Simulation models are used to generate our business estimates and forecasts. For each study, a one-of-a-kind model is created. Data gathered for market dynamics, the digital landscape, development services, and valuation patterns are fed into the prototype and analyzed concurrently. These factors are compared, and their effect over the projected timeline is quantified using correlation, regression, and statistical modeling. Market forecasting is accomplished through the use of a combination of economic techniques, technical analysis, industry experience, and domain knowledge.
Short-term forecasting is typically done with econometric models, while long-term forecasting is done with technological market models. These are based on a synthesis of the technological environment, legal frameworks, economic outlook, and business regulations. Bottom-up market evaluation is favored, with crucial regional markets reviewed as distinct entities and data integration to acquire worldwide estimates. This is essential for gaining a thorough knowledge of the industry and ensuring that errors are kept to a minimum.
Some of the variables taken into account for forecasting are as follows:
• Industry drivers and constraints, as well as their current and projected impact
• The raw material case, as well as supply-versus-price trends
• Current volume and projected volume growth through 2032
We allocate weights to these variables and use weighted average analysis to determine the estimated market growth rate.
Primary Validation
This is the final step in our report’s estimating and forecasting process. Extensive primary interviews are carried out, both in-person and over the phone, to validate our findings and the assumptions that led to them.
Leading companies from across the supply chain, including suppliers, technology companies, subject matter experts, and buyers, use techniques like interviewing to ensure a comprehensive and non-biased overview of the business. These interviews are conducted all over the world, with the help of local staff and translators, to overcome language barriers.
Primary interviews not only aid with data validation, but also offer additional important insight into the industry, existing business scenario, and future projections, thereby improving the quality of our reports.
All of our estimates and forecasts are validated through extensive research work with key industry participants (KIPs), which typically include:
• Market leaders
• Suppliers of raw materials
• Suppliers of raw materials
• Buyers.
The following are the primary research objectives:
• To ensure the accuracy and acceptability of our data.
• Gaining an understanding of the current market and future projections.
Data Collection Matrix
| Perspective | Primary research | Secondary research |
| Supply-side |
|
|
| Demand-side |
|
|
Market Analysis Matrix
| Qualitative analysis | Quantitative analysis |
|
|
Prominent Player
- Zoetis Inc.
- Elanco Animal Health
- Boehringer Ingelheim Animal Health
- Virbac
- Aratana Therapeutics
- AB Science
- VetDC Inc.
- Regeneus Ltd.
- CanFel Therapeutics
- Merial
- Karyopharm Therapeutics Inc.
- Rhizen Pharmaceuticals SA
- Vetoquinol S.A.
- Ceva Santé Animale
- Sentia Medical Sciences Inc.
- Others
FAQs
The key factors driving the Market are Increasing Pet Ownership, Advancements in Veterinary Medicine, Rising Incidence of Pet Cancer, Growing Awareness and Education, Personalized Medicine for Pets And Expansion of Telemedicine and Remote Consultations.
The “Lymphoma” category dominated the market in 2023.
The key players in the market are Zoetis Inc., Elanco Animal Health, Boehringer Ingelheim Animal Health, Virbac, Aratana Therapeutics, AB Science, VetDC Inc., Regeneus Ltd., CanFel Therapeutics, Merial, Karyopharm Therapeutics Inc., Rhizen Pharmaceuticals SA, Vetoquinol S.A., Ceva Santé Animale, Sentia Medical Sciences Inc., Others.
“North America” had the largest share in the Pet Cancer Therapeutics Market.
The global market is projected to grow at a CAGR of 9.2% during the forecast period, 2024-2033.
The Pet Cancer Therapeutics Market size was valued at USD 526.5 Million in 2024.